Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + double-platinum chemotherapy vs osimertinib in first-line advanced NSCLC with high PD-L1 and EGFR-sensitive mutations
ChiCTR2400093087Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: progression-free survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
sintilimabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400093087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093087.